Altimmune, Inc.
$2.91
The Read: Altimmune's stock rallied about 24% after securing $225 million in oversubscribed financing that resolved cash concerns through Phase 3 data, but then declined around 11% as in-line earnings and plans for costly solo Phase 3 trials raised cash burn worries.
Price
Overlays
Panel
ALT
Hover to view data
No Data
